Paclitaxel + Carboplatin + MEDI4736 + MEDI9447
Phase 1/2Active 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer
Conditions
Triple Negative Breast Cancer
Trial Timeline
Dec 28, 2018 → Dec 1, 2025
NCT ID
NCT03616886About Paclitaxel + Carboplatin + MEDI4736 + MEDI9447
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447 is a phase 1/2 stage product being developed by AstraZeneca for Triple Negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03616886. Target conditions include Triple Negative Breast Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03616886 | Phase 1/2 | Active |
Competing Products
20 competing products in Triple Negative Breast Cancer